480 Study: Phase 2b Open-label, Randomized Study in Treatment Naive Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron Plus Ribavirin Given Bi-Weekly to PEG-Intron Plus Ribavirin Given Weekly.

Trial Profile

480 Study: Phase 2b Open-label, Randomized Study in Treatment Naive Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron Plus Ribavirin Given Bi-Weekly to PEG-Intron Plus Ribavirin Given Weekly.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EMPOWER
  • Sponsors Biolex
  • Most Recent Events

    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Dec 2010 Tolerability results from EMPOWER have been presented as a late-breaker at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
    • 02 Nov 2010 Results reported at AASLD, according to a OctoPlus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top